The Effect of Rivaroxaban in the Treatment of Lower Limb Deep Vein Thrombosis Patients with Different Levels of D-D Expression
Objective:To analyze the effect of Rivaroxaban in the treatment of lower limb deep vein thrombosis with different D-dimer(D-D)expression levels.Method:A total of 100 patients with lower limb deep vein thrombosis admitted to Songzi People's Hospital from October 2022 to October 2023 as the research subjects,with a D-D level of 0.6 mg/L as the critical value,49 patients with D-D>0.6 mg/L were selected as the high expression group,and 51 patients with D-D≤0.6 mg/L were selected as the low expression group.Both groups were treated with Rivaroxaban.The hemodynamics,hemorheology,endothelial function indexes,inflammatory factors and therapeutic effect of two groups were detected and compared.Result:After treatment,the levels of central venous pressure(CVP)and mean arterial pressure(MAP)in two groups were increased compared to those before treatment,and those in the low expression group were higher than those in the high expression group,and plasma viscosity,whole blood low shear viscosity,whole blood high shear viscosity,von willefibrilia factor(vWF),endothelin(ET),macrophage inflammatory protein 1α(MIP-1α)and C reactive protein(CRP)levels were decreased compared to those before treatment,and those in low expression group were lower than those in the high expression group(P<0.05).Compared with high expression group,the total effective rate of low expression group was higher,the difference was statistically significant(P<0.05).Conclusion:Patients with deep vein thrombosis in the lower limbs with D-D≤0.6 mg/L showed improvement in hemodynamics and hemorheology after treatment with Rivaroxaban,with significant reduction in endothelial injury and inflammatory response,resulting in more ideal outcomes.